ArticleCancer management and research2019
Long-term survival after percutaneous irreversible electroporation of inoperable colorectal liver metastases.
Article in Cancer management and research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Efficacy and safety of irreversible electroporation for malignant liver tumors: a systematic review and meta-analysis.European radiology · 2021Pooled it
- Irreversible Electroporation for Colorectal Liver Metastases: Long-term Outcomes from a Transatlantic Multicenter Study.Cardiovascular and interventional radiology · 2026Article
- Interventional radiological therapies in colorectal hepatic metastases.Frontiers in oncology · 2023Review
- Irreversible electroporation versus radiofrequency ablation for malignant hepatic tumor: A prospective single-center double-arm trial.Journal of interventional medicine · 2022Article
- Contemporary evidence on colorectal liver metastases ablation: toward a paradigm shift in locoregional treatment.International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2022Article
- Review
- Image-Guided Ablation for Colorectal Liver Metastasis: Principles, Current Evidence, and the Path Forward.Cancers · 2021Review
- The Role of Percutaneous Ablation in the Management of Colorectal Cancer Liver Metastatic Disease.Diagnostics (Basel, Switzerland) · 2021Review
- Article
- Irreversible Electroporation: Background, Theory, and Review of Recent Developments in Clinical Oncology.Bioelectricity · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFor colorectal liver metastases (CRLM) that are not amenable to surgery or thermal ablation, irreversible electroporation (IRE) is a novel local treatment modality and additional option.
methodsThis study is a retrospective long-term follow-up of patients with CRLM who underwent IRE as salvage treatment.
resultsOf the 24 included patients, 18 (75.0%) were male, and the median age was 57 (range: 28-75) years. The mean time elapsed from diagnosis to IRE was 37.9±37.3 months. Mean overall survival was 26.5 months after IRE (range: 2.5-69.2 months) and 58.1 months after diagnosis (range: 14.8-180.1 months). One-, three-, and five-year survival rates after initial diagnosis were 100.0%, 79.2%, and 41.2%; after IRE, the respective survival rates were 79.1%, 25.0%, and 8.3%. There were no statistically significant differences detected in survival after IRE with respect to gender, age, T- or N-stage at the time of diagnosis, size of metastases subject to IRE, number of hepatic lesions, or time elapsed between IRE and diagnosis.
conclusionFor nonresectable CRLM, long-term survival data emphasize the value of IRE as a new minimally invasive local therapeutic approach in multimodal palliative treatment, which is currently limited to systemic or regional therapies in this setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.